Haptoglobin Phenotype, Preeclampsia Risk and the Efficacy of Vitamin C and E Supplementation to Prevent Preeclampsia in a Racially Diverse Population

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Weissgerber, Tracey L ^a   Gandley, Robin E ^b   McGee, Paula L ^c   Spong, Catherine Y ^d   Myatt, Leslie ^e   Leveno, Kenneth J ^f   Thorp, John M ^g   Mercer, Brian M ^h   Peaceman, Alan M ⁱ   Ramin, Susan M ^j   Carpenter, Marshall W ^k   Samuels, Philip ^l   Sciscione, Anthony ^m   Harper, Margaret ⁿ   Tolosa, Jorge E ^o   Saade, George ^p   Sorokin, Yoram ^q  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k BROWN UNIVERSITY   (United States)

^l OHIO STATE UNIVERSITY   (United States)

^m DREXEL UNIVERSITY   (United States)

ⁿ WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^o OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^p UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^q WAYNE STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CREATININE; HAPTOGLOBIN; LIVER ENZYME;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; ECLAMPSIA; FEMALE; HISPANIC; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; PERINATAL DEATH; PHENOTYPE; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE LABOR; RACE DIFFERENCE; RISK FACTOR; RISK REDUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

EID: 84875716968     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060479     Document Type: Article

References (49)

1. Hauth JC, Ewell MG, Levine RJ, Esterlitz JR, Sibai B, et al. (2000) Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol 95: 24-28.
2. Knuist M, Bonsel GJ, Zondervan HA, Treffers PE, (1998) Intensification of fetal and maternal surveillance in pregnant women with hypertensive disorders. Int J Gynaecol Obstet 61: 127-133.
3. World Health Organization (2005) World Health Report: Make Every Mother, and Child Count. Geneva: WHO.
4. Altman D, Carroli G, Duley L, Farrell B, Moodley J, et al. (2002) Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 359: 1877-1890.
5. Maynard SE, Min JY, Merchan J, Lim KH, Li J, et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658.
6. Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, et al. (2002) A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 187: 127-136.
7. Gupta S, Aziz N, Sekhon L, Agarwal R, Mansour G, et al. (2009) Lipid peroxidation and antioxidant status in preeclampsia: a systematic review. Obstet Gynecol Surv 64: 750-759.
8. Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, et al. (1999) Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 354: 810-816.
9. Villar J, Purwar M, Merialdi M, Zavaleta N, Thi Nhu Ngoc N, et al. (2009) World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG 116: 780-788.
10. Beazley D, Ahokas R, Livingston J, Griggs M, Sibai BM, (2005) Vitamin C and E supplementation in women at high risk for preeclampsia: a double-blind, placebo-controlled trial. Am J Obstet Gynecol 192: 520-521.
11. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH, (2006) Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP Trial): randomised placebo-controlled trial. Lancet 367: 1145-1154.
12. Spinnato JA 2nd, Freire S, Pinto ESJL, Cunha Rudge MV, Martins-Costa S, et al (2007) Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. Obstet Gynecol 110: 1311-1318.
13. Xu H, Perez-Cuevas R, Xiong X, Reyes H, Roy C, et al. (2010) An international trial of antioxidants in the prevention of preeclampsia (INTAPP). Am J Obstet Gynecol 202: 239 e231-239 e210.
14. Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, et al. (2010) Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 362: 1282-1291.
15. Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS, (2006) Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 354: 1796-1806.
16. Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R,et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal 12: 293-304.
17. Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, et al. (1993) Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 91: 977-985.
18. Levy AP, Gerstein HC, Miller-Lotan R, Ratner R, McQueen M, et al. (2004) The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 27: 2767.
19. Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, et al. (2008) Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 28: 341-347.
20. Blum S, Vardi M, Brown JB, Russell A, Milman U, et al. (2010) Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics 11: 675-684.
21. Levy AP, Friedenberg P, Lotan R, Ouyang P, Tripputi M, et al. (2004) The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women. Diabetes Care 27: 925-930.
22. Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, et al. (2010) Haptoglobin: basic and clinical aspects. Antioxid Redox Signal 12: 293-304.
23. Langlois MR, Delanghe JR, (1996) Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42: 1589-1600.
24. Weissgerber TL, Roberts JM, Jeyabalan A, Powers RW, Lee M, et al. (2012) Haptoglobin phenotype, angiogenic factors, and preeclampsia risk. Am J Obstet Gynecol 206: 358 e310-318.
25. Gaensslen RE, Bell SC, Lee HC, (1987) Distributions of genetic markers in United States populations: III. Serum group systems and hemoglobin variants. J Forensic Sci 32: 1754-1774.
26. Blum S, Milman U, Shapira C, Miller-Lotan R, Bennett L, et al. (2008) Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler Thromb Vasc Biol 28: e18-20.
27. Blum S, Vardi M, Levy NS, Miller-Lotan R, Levy AP, (2010) The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis 211: 25-27.
28. Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, et al. (2008) Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 57: 2794-2800.
29. Ury HK, (1975) Efficiency of Case-Control Studies with Multiple Controls Per Case: Continuous or Dichotomous Data. Biometrics 31: 643-649.
30. Weissgerber TL, Gandley RE, Roberts JM, Patterson CC, Holmes VA,et al. (in review) Haptoglobin phenotype and preeclampsia incidence in women with Type 1 Diabetes supplemented with Vitamins C and E.
31. Simon JA, Murtaugh MA, Gross MD, Loria CM, Hulley SB, et al. (2004) Relation of ascorbic acid to coronary artery calcium: the Coronary Artery Risk Development in Young Adults Study. Am J Epidemiol 159: 581-588.
32. Lumey Thomas (2010) Complex surveys: A guide to analysis using R. Hoboken, NJ: John Wiley & Sons.
33. Rao JNK, Scott AJ, (1981) The analysis of categorical data from complex sample surveys: chi-squared tests for goodness-of-fit and independence in two-way tables. Journal of the American Statistical Association 76: 221-230.
34. Siegel Castellan (1988) Non parametric statistics for the behavioural sciences. New York: McGraw Hill Int.
35. Cahill LE, El-Sohemy A, (2010) Haptoglobin genotype modifies the association between dietary vitamin C and serum ascorbic acid deficiency. Am J Clin Nutr 92: 1494-1500.
36. Depypere HT, Langlois MR, Delanghe JR, Temmerman M, Dhont M, (2006) Haptoglobin polymorphism in patients with preeclampsia. Clin Chem Lab Med 44: 924-928.
37. Sammour RN, Nakhoul FM, Levy AP, Miller-Lotan R, Nakhoul N, et al. (2010) Haptoglobin phenotype in women with preeclampsia. Endocrine 38: 303-308.
38. Raijmakers MT, Roes EM, te Morsche RH, Steegers EA, Peters WH, (2003) Haptoglobin and its association with the HELLP syndrome. J Med Genet 40: 214-216.
39. Goldenstein H, Levy N, Levy A, (2012) Involvement of haptoglobin in prevention of oxidative stress caused by hemoglobin in preeclampsia. Advances in Bioscience and Biotechnology 3: 1037-1042.
40. Roberts JM, Lain KY, (2002) Recent Insights into the pathogenesis of pre-eclampsia. Placenta 23: 359-372.
41. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, et al. (2011) Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. J Am Coll Cardiol 57: 1404-1423.
42. Landon MB, Gabbe SG, (2011) Gestational diabetes mellitus. Obstet Gynecol 118: 1379-1393.
43. Wendland EM, Torloni MR, Falavigna M, Trujillo J, Dode MA, et al. (2012) Gestational diabetes and pregnancy outcomes- a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria. BMC Pregnancy Childbirth 12: 23.
44. Jensen DM, Damm P, Ovesen P, Molsted-Pedersen L, Beck-Nielsen H, et al. (2010) Microalbuminuria, preeclampsia, and preterm delivery in pregnant women with type 1 diabetes: results from a nationwide Danish study. Diabetes Care 33: 90-94.
45. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, et al. (2003) The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Archives of internal medicine 163: 427-436.
46. Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, et al. (2012) First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstetrics and gynecology 119: 1234-1242.
47. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C (2008) Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev: CD007176.
48. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P, (2000) Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 154-160.
49. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, et al. (2002) Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 288: 2432-2440.